Verastem, Inc. , focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that VS-5584 has received orphan medicinal product designation from the European Commission for use in mesothelioma. The designation was created to encourage the development of drugs that may provide significant benefit to patients suffering from rare diseases.
http://ift.tt/1xS8Lct
http://ift.tt/1xS8Lct
No comments:
Post a Comment